Other infective spondylopathies

M13_SPONDYLOINFECTION

spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.

Suggest a new description

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 M46.5
  • Cause of death: ICD-10 M46.5

2 out of 7 registries used, show all original rules.

76

4. Check minimum number of events

None

76

5. Include endpoints

None

76

6. Filter based on genotype QC (FinnGen only)

76

Control definitions (FinnGen only)

Control exclude
M13_DORSOPATHY

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M46
Name in latin
Aliae spondylopathiae infectiosae

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 542 218 318
Only index persons 472 194 278
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 62.03 62.76 61.63
Only index persons 61.15 61.14 61.16

-FinnGen-

Key figures

All Female Male
Number of individuals 76 36 40
Unadjusted period prevalence (%) 0.02 0.01 0.02
Median age at first event (years) 61.74 61.75 61.74

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
69
Matched controls
691
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.5
ICD-10 Finland
Other infective spondylopathies
+∞
99.1
69
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
19.7
18
*
M48.0
ICD-10 Finland
Spinal stenosis
128.5
18.6
19
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
85.7
17.8
19
*
N02AX02
ATC
tramadol; systemic, rectal
9.7
16.6
51
156
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
16.3
15
*
N03AX16
ATC
pregabalin; oral
8.2
12.3
31
62
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
11.8
11
*
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
10.7
10
*
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
+∞
10.7
10
*
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
64.4
10.0
11
*
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
35.7
9.8
12
*
J01FF01
ATC
clindamycin; systemic
5.3
9.2
34
106
M54.5
ICD-10 Finland
Low back pain
5.3
8.3
29
83
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.7
8.3
36
130
N02AA05
ATC
oxycodone; systemic
6.1
8.3
24
55
J04AB02
ATC
rifampicin; systemic
51.0
7.9
9
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
13.0
7.7
13
12
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
7.7
7.4
17
28
M54.2
ICD-10 Finland
Cervicalgia
25.5
6.9
9
*
M45
ICD-10 Finland
Ankylosing spondylitis
+∞
6.3
6
*

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
43
158
4.96
11.04
9.8
3.9
—
—
—
0
0
27
80
4.68
8.81
2.9
1.9
—
—
—
0
0
39
185
3.28
6.08
11.0
4.9
—
—
—
0
0
23
79
3.74
5.93
18.0
25.4
1.3
1.5
inr
—
7
11
13
32
4.69
5.13
15.5
8.3
26.3
24.8
mmol/l
0.75
13
32
35
172
2.92
4.91
5.5
3.1
—
—
—
0
0
8
7
12.57
4.90
5.1
3.3
—
—
—
0
0
53
328
3.03
4.80
18.0
9.7
4.8
4.1
e9/l
1.09
48
295
36
184
2.82
4.64
2.5
2.3
—
—
—
0
0
7
6
12.66
4.36
2.1
3.5
—
—
—
0
0
38
209
2.64
4.14
4.5
3.7
27.8
67.2
e6/l
0.82
29
149
35
185
2.65
4.13
3.8
3.3
22.4
407.8
e6/l
0.55
28
139
16
55
3.42
4.02
3.6
1.8
0.2
0.2
g/l
0.88
16
50
7
8
9.48
3.86
8.3
1.5
9.1
9.0
kpa
—
7
8
7
8
9.48
3.86
8.3
1.5
5.4
5.2
kpa
—
7
8
31
162
2.54
3.66
4.1
3.1
0.3
0.4
e6/l
0.16
25
122
10
26
4.28
3.65
10.4
2.9
—
—
—
0
0
7
9
8.42
3.64
1.0
1.0
—
—
—
0
0
55
387
2.52
3.25
5.5
4.1
—
—
—
0
0
23
110
2.56
3.21
8.4
3.8
—
—
—
0
0
13
45
3.28
3.21
4.8
2.3
—
—
—
0
0
6
8
8.02
3.11
2.7
1.4
—
—
—
0
0
41
258
2.28
3.08
22.3
8.9
0.0
0.0
e9/l
0.71
35
218
5
5
10.57
3.02
1.8
1.4
2.0
1.4
mmol/l
—
5
5
28
152
2.33
2.95
4.4
2.9
—
—
—
0
0
11
36
3.40
2.94
21.4
8.9
93.6
94.4
%
0.31
11
36
7
13
5.81
2.94
1.3
1.2
—
—
—
0
0
15
60
2.87
2.91
1.2
1.6
—
—
—
0
0
6
10
6.40
2.75
1.3
1.3
—
—
—
0
0
11
38
3.22
2.71
5.9
2.7
—
—
—
0
0
17
76
2.59
2.68
1.2
1.2
—
—
—
0
0
40
261
2.12
2.63
7.1
3.9
31.9
35.5
g/l
2.72
40
243
5
7
7.54
2.59
1.0
1.1
—
—
—
0
0
15
64
2.67
2.58
1.3
1.4
—
—
—
0
0
6
12
5.32
2.45
1.8
1.6
34.7
34.3
umol/l
—
6
12
8
22
3.94
2.44
6.4
2.3
0.9
1.6
mmol/l
—
8
22
15
66
2.59
2.43
1.7
1.2
—
—
—
0
0
23
124
2.23
2.41
8.5
5.9
—
—
—
0
0
5
8
6.59
2.41
1.0
1.0
—
—
—
0
0
9
28
3.50
2.40
1.3
1.2
—
—
—
0
0
26
148
2.15
2.39
10.8
6.6
—
—
—
0
0
15
67
2.54
2.36
1.6
1.4
240.0
344.0
titre
—
5
20
13
55
2.65
2.27
1.8
1.6
—
—
—
0
0
16
76
2.40
2.22
4.7
5.2
1.2
1.0
mmol/l
0.54
16
70
6
14
4.55
2.19
1.3
1.1
—
—
—
0
0
36
239
1.96
2.14
1.8
1.9
93.4
87.8
pmol/l
0.27
17
112
16
78
2.33
2.09
1.5
1.8
—
—
—
0
0
37
251
1.92
2.05
12.0
7.2
1.7
1.3
inr
0.37
11
77
10
39
2.80
2.01
8.2
2.7
10.0
9.7
g/l
—
10
33
10
39
2.80
2.01
23.2
8.3
1.6
1.2
%
—
10
39
10
39
2.80
2.01
23.2
8.3
0.6
0.6
%
—
10
39
0
50
0.00
1.97
0.0
1.4
—
—
—
0
0
10
40
2.73
1.92
14.5
3.7
—
—
—
0
0
39
275
1.86
1.87
7.7
3.5
0.0
0.0
estimate
—
7
53
12
54
2.45
1.85
21.0
7.3
—
—
—
0
0
10
42
2.59
1.76
5.9
2.2
0.6
0.7
%
—
10
42
39
280
1.81
1.73
7.9
3.5
0.0
0.0
estimate
—
6
50
39
280
1.81
1.73
10.2
4.9
0.0
0.0
estimate
—
8
55
10
43
2.53
1.68
6.8
2.2
1.2
1.2
%
—
10
43
13
65
2.21
1.60
5.9
2.6
—
—
—
0
0
27
177
1.81
1.59
7.5
4.0
7.4
7.4
ph
—
7
34
17
97
1.97
1.50
2.3
1.6
4.3
2.3
g/l
0.86
11
57
13
67
2.13
1.49
1.4
1.2
—
—
—
0
0
11
54
2.21
1.41
8.9
3.9
1.2
1.2
mmol/l
0.40
11
47
6
23
2.74
1.39
3.2
3.0
—
—
—
0
0
9
42
2.29
1.39
1.1
1.5
—
—
—
0
0
5
19
2.74
1.23
1.4
1.8
—
—
—
0
0
31
226
1.63
1.20
2.2
2.2
—
—
—
0
0
8
40
2.12
1.16
7.1
4.5
—
—
—
0
0
17
106
1.78
1.15
6.5
3.1
0.8
0.8
mmol/l
0.36
17
100
14
82
1.87
1.14
1.1
1.2
0.8
25.0
u/ml
—
7
25
15
91
1.81
1.10
1.3
1.2
55.6
42.4
iu/ml
—
6
33
34
258
1.58
1.10
6.1
3.5
30.9
54.9
ng/l
0.77
28
190
29
212
1.59
1.10
2.9
3.2
49.0
67.0
mg/l
0.31
18
133
10
53
2.02
1.07
4.8
3.8
—
—
—
0
0
66
595
1.83
0.96
44.7
12.9
36.0
23.1
mg/l
1.91
60
459
6
28
2.24
0.94
31.2
7.6
—
—
—
0
0
8
43
1.96
0.91
3.3
2.8
—
—
—
0
0
28
214
1.49
0.84
2.9
3.2
6.0
7.7
mmol/l
2.16
23
181
5
23
2.25
0.77
2.4
1.8
—
—
—
0
0
20
146
1.50
0.74
9.9
3.7
0.0
0.0
estimate
—
8
53
58
626
0.69
0.60
5.3
5.2
2.5
2.6
mmol/l
0.53
52
560
0
23
0.00
0.59
0.0
1.1
—
—
—
0
0
58
532
1.38
0.51
39.2
14.3
39.1
40.0
%
0.30
34
366
7
45
1.61
0.50
1.6
1.4
—
—
—
0
0
7
47
1.54
0.49
5.6
3.4
—
—
—
0
0
17
214
0.74
0.46
3.4
3.2
—
—
—
0
0
27
225
1.31
0.46
3.7
4.1
8.4
11.9
mg/mmol
0.26
16
138
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
5
35
1.46
0.40
1.2
1.2
—
—
—
0
0
23
191
1.29
0.40
5.3
4.1
—
—
—
0
0
47
434
1.22
0.30
4.1
3.9
—
—
—
0
0
45
416
1.20
0.28
3.0
3.8
14.6
15.2
pmol/l
0.61
38
364
5
37
1.38
0.24
1.0
1.2
—
—
—
0
0
66
638
1.26
0.21
42.6
15.3
139.1
139.7
mmol/l
1.20
66
614
7
61
1.16
0.18
1.4
1.3
—
—
—
0
0
66
674
0.84
0.11
53.8
19.3
251.1
243.9
e9/l
0.30
66
654
66
674
0.84
0.11
53.5
19.2
30.0
30.4
pg
1.25
66
661
66
674
0.84
0.11
53.7
19.3
91.4
91.3
fl
0.06
66
661
6
58
1.04
0.08
1.2
1.3
—
—
—
0
0
15
137
1.12
0.08
1.3
1.3
—
—
—
0
0
61
623
0.89
0.08
27.9
12.5
—
—
—
0
0
66
649
1.13
0.06
42.9
16.1
77.4
80.1
umol/l
0.40
66
649
50
492
1.05
0.02
47.2
16.5
14.5
13.8
%
2.34
50
486
17
167
1.02
0.00
6.3
3.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
52
0.96
0.00
1.2
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
2.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
5
51
0.98
0.00
1.8
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
6.2
—
36.8
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint M13_SPONDYLOINFECTION and mortality.

Females

Parameter HR [95% CI] p-value
M13_SPONDYLOINFECTION 1.757 [1.21, 2.55] 0.003
Birth year 0.998 [0.99, 1.01] 0.609

During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 189 females with M13_SPONDYLOINFECTION died.

Males

Parameter HR [95% CI] p-value
M13_SPONDYLOINFECTION 1.879 [1.35, 2.62] < 0.001
Birth year 0.986 [0.98, 1.0] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 102 out of 266 males with M13_SPONDYLOINFECTION died.

Mortality risk

Mortality risk for people of age

years, who have M13_SPONDYLOINFECTION.

N-year risk Females Males
1 0.202% 0.326%
5 1.082% 2.174%
10 2.763% 5.34%
15 5.439% 9.837%
20 9.668% 17.039%

Relationships between endpoints

Index endpoint: M13_SPONDYLOINFECTION – Other infective spondylopathies

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data